Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Musculoskelet Disord ; 20(1): 17, 2019 Jan 08.
Article in English | MEDLINE | ID: mdl-30621690

ABSTRACT

BACKGROUND: Osteoid osteoma is a painful benign skeletal tumour of unknown aetiology. Most often it occurs in the long bones of extremities and responds well to nonsteroidal anti-inflammatory medications. However, unusual localization and atypical presentation of this tumour might present a diagnostic challenge, especially if symptoms mimic that indicative of juvenile spondyloarthritis. CASE PRESENTATION: A misdiagnosed ten-and-a-half-year-old girl with osteoid osteoma involving the distal phalanx of a little finger is presented. Her initial symptoms were pain and swelling of the little finger resembling dactylitis, while various imaging modalities showed signs of tenosynovitis, indicating a possible development of juvenile spondyloarthritis. Several trials of different non-steroid anti-inflammatory drugs gave no satisfactory results and ultrasound guided triamcinolone-hexacetonide injection provided only a short relief. Finally, almost three years after initial presentation, persistent clinical symptoms warranted repeated imaging that raised suspicion of an osteoid osteoma. Directed treatment with surgical intervention led to almost immediate and complete resolution of her symptoms. CONCLUSIONS: Osteoid osteoma should be suspected in case of a tender swelling of a digit in children and adolescents, regardless of initial imaging findings and clinical presentation. Early diagnosis and treatment of this benign condition can have a substantial impact on quality of life of patients and their families and protect them from many unnecessary diagnostic procedures and treatment.


Subject(s)
Arthritis, Juvenile/diagnosis , Bone Neoplasms/diagnosis , Osteoma, Osteoid/diagnosis , Pain/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Juvenile/drug therapy , Child , Diagnosis, Differential , Diagnostic Errors , Female , Finger Phalanges/diagnostic imaging , Finger Phalanges/pathology , Finger Phalanges/surgery , Humans , Magnetic Resonance Imaging , Osteoma, Osteoid/complications , Osteoma, Osteoid/pathology , Osteoma, Osteoid/surgery , Pain/etiology , Treatment Outcome
2.
J Foot Ankle Surg ; 57(6): 1246-1252, 2018.
Article in English | MEDLINE | ID: mdl-30177452

ABSTRACT

Longitudinal epiphyseal bracket (LEB) is a rare bone dysplasia of the tubular bones. Owing to an abnormal secondary ossification center, the affected bones can develop progressive shortening and angular deformity. The aim of our study was to provide an overview of the reported data regarding epidemiology and surgical procedures available for LEB of the first metatarsal bone in a pediatric population combined with a small case series. We report a retrospective case series of 3 nonsyndromic pediatric patients with different ages and with confirmed dysplasia of the first metatarsal bone. All patients presented with unilateral congenital hallux varus deformity and underwent surgical treatment. The radiographs and medical records were reviewed to evaluate the deformity characteristics, treatment, and clinical results. The mean patient age at initial surgery was 34 (range 12 to 63) months, and the median follow-up period was 46 (range 31 to 75) months. Almost all specific radiographic measurements showed correction of the deformity, and each foot demonstrated functional and cosmetic improvement. A standardized literature search was performed to obtain studies of LEB of the first metatarsal bone in the pediatric population. From on our results and the current data available, surgical treatment should be tailored to the patient's age and radiographic stage of LEB. However, monitoring until skeletal maturity of the feet is necessary to assess the final results.


Subject(s)
Bone Diseases, Developmental/surgery , Foot Deformities, Congenital/surgery , Hallux Varus/surgery , Metatarsal Bones/abnormalities , Metatarsal Bones/surgery , Bone Diseases, Developmental/etiology , Child, Preschool , Epiphyses/surgery , Female , Foot Deformities, Congenital/etiology , Hallux Varus/etiology , Humans , Infant , Infant, Newborn , Male
3.
Vascul Pharmacol ; 106: 54-66, 2018 07.
Article in English | MEDLINE | ID: mdl-29510201

ABSTRACT

Rat inferior caval vein (ICV) ligation (up to the right ovarian vein (ROV)) commonly represents a recapitulation of Virchow: with ligation leading to vessel injury, stasis, thrombosis and hemodynamic changes. We revealed that BPC 157's therapy collectively attenuated or counteracted all these events and the full syndrome. METHODS: We applied BPC 157 (10 µg, 10 ng/kg) as an early regimen or as a delayed therapy. Assessment includes gross assessment by microcamera; microscopy, venography, bleeding, blood pressure, ECG, thermography, MDA and NO-level in plasma and ICV, and gene expression. RESULTS: Direct vein injury, thrombosis, thrombocytopenia, prolonged bleeding were all counteracted. Also, rapid presentation of collaterals and redistribution of otherwise trapped blood volume (bypassing through the left ovarian vein (LOV) and other veins), with venous hypertension, arterial hypotension and tachycardia counteraction were shown. BPC 157-rats presented raised plasma NO-values, but normal MDA-values; in ICV tissue reverted low NO-values and counteracted increased MDA-levels. Altered expression of EGR, NOS, SRF, VEGFR and KRAS in ICV, ROV and LOV revealed increased or decreased levels, while some genes continuously remained unchanged. CONCLUSION: As a new insight, BPC 157 application largely attenuated or even completely eliminated all consequences of ICV ligation in rats.


Subject(s)
Fibrinolytic Agents/pharmacology , Peptide Fragments/pharmacology , Proteins/pharmacology , Vena Cava, Inferior/surgery , Venous Thrombosis/prevention & control , Animals , Biomarkers/blood , Collateral Circulation/drug effects , Disease Models, Animal , Electrocardiography , Female , Gene Expression Regulation , Hemodynamics/drug effects , Hemorrhage/prevention & control , Ligation , Male , Malondialdehyde/blood , Nitric Oxide/blood , Phlebography , Rats, Wistar , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Thermography , Thrombocytopenia/blood , Thrombocytopenia/prevention & control , Time Factors , Vena Cava, Inferior/metabolism , Vena Cava, Inferior/pathology , Vena Cava, Inferior/physiopathology , Venous Thrombosis/blood , Venous Thrombosis/genetics , Venous Thrombosis/physiopathology
4.
PLoS One ; 10(4): e0123454, 2015.
Article in English | MEDLINE | ID: mdl-25897838

ABSTRACT

BACKGROUND: BPC 157 is a stable gastric pentadecapeptide recently implicated with a role in hemostasis. While NO is largely implicated in hemostatic mechanisms, in tail-amputation-models under heparin- and warfarin-administration, both the NO-synthase (NOS)-blocker, L-NAME (prothrombotic) and the NOS-substrate L-arginine (antithrombotic), were little investigated. Objective. To investigate the effect of L-NAME and L-arginine on hemostatic parameters, and to reveal the effects of BPC 157 on the L-NAME- and L-arginine-induced hemostatic actions under different pathological condition: tail amputation without or with anticoagulants, heparin or warfarin. METHODS: Tail amputation, and/or i.v.-heparin (10 mg/kg), i.g.-warfarin (1.5 mg/kg/day for 3 days) were used in rats. Treatment includes BPC 157, L-NAME, L-arginine, per se and their combination. RESULTS: After (tail) amputation, with or without i.v.-heparin or i.g.-warfarin, BPC 157 (10 µg/kg, 10 ng/kg, i.p., i.v. (heparin), 10 µg/kg i.g. (warfarin)) always reduced bleeding time and/or haemorrhage and counteracted thrombocytopenia. As for L-NAME and/or L-arginine, we noted: L-arginine (100 mg/kg i.p.)-rats: more bleeding, less/no thrombocytopenia; L-NAME (5 mg/kg i.p.)-rats: less bleeding (amputation only), but present thrombocytopenia; L-NAME+L-arginine-rats also exhibited thrombocytopenia: L-NAME counteracted L-arginine-increased bleeding, L-arginine did not counteract L-NAME-thrombocytopenia. All animals receiving BPC 157 in addition (BPC 157 µg+L-NAME; BPC 157 µg+L-arginine, BPC 157 µg+L-NAME+L-arginine), exhibited decreased haemorrhage and markedly counteracted thrombocytopenia. CONCLUSIONS: L-NAME (thrombocytopenia), L-arginine (increased haemorrhage) counteraction and BPC 157 (decreased haemorrhage, counteracted thrombocytopenia) with rescue against two different anticoagulants, implicate a BPC 157 modulatory and balancing role with rescued NO-hemostatic mechanisms.


Subject(s)
Anticoagulants/pharmacology , Hemorrhage/drug therapy , Heparin/pharmacology , Peptide Fragments/pharmacology , Proteins/pharmacology , Thrombocytopenia/drug therapy , Warfarin/pharmacology , Amputation, Surgical , Animals , Arginine , Drug Evaluation, Preclinical , Hemorrhage/chemically induced , Hemostasis , Male , NG-Nitroarginine Methyl Ester , Peptide Fragments/therapeutic use , Proteins/therapeutic use , Rats, Wistar , Thrombocytopenia/chemically induced
5.
Iran Red Crescent Med J ; 15(2): 157-60, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23682329

ABSTRACT

BACKGROUND: Chronic abdominal pain (CAP) is a serious medical condition which needs to be approached with great attention. Chronic abdominal pain may be caused by entrapment of cutaneous branches of intercostal nerves (ACNES). OBJECTIVES: The aim of this study is the surgery for abdominal wall pain which caused by cutaneous nerve entrapment in children during last 5 years. MATERIALS AND METHODS: In all children with ACNES, we tried conservative treatment with anesthetic and steroid injections. In children who were refractory to conservative treatment, we received surgical procedure like sectioning the entrapped nerve to obtain relief. RESULTS: In 12 pediatric patients with chronic abdominal pain, we diagnosed ACNES. Each presented with abdominal pain and a positive Carnett sign. Local nerve blocks using anesthetic and steroid injections are the treatment. In all patients, we tried with local nerve block. In 3 patients, pain improvement occurs in the few minutes, and they were without pain after 5 days. In other 4 patients required a reinjection for pain recurrence. In one patients pain was gone. The maximum reinjection was 3. In other 5 patients, we did operative treatment like sectioning the entrapped nerve. CONCLUSIONS: Some children with CAP have ACNES. In all children with ACNES, we recommended local nerve blocks. If the local block in 3 times is not helping, neurectomy of the peripheral nerve is method of choice.

6.
Coll Antropol ; 36(2): 627-33, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22856255

ABSTRACT

The problem of low back pain (LBP) in children is very common and many specialists are dealing with it in everyday practice. The cause for low back pain often is not found and classified under the diagnosis of non specific low back pain. The objective of this prospective study is to determine wether children with non specific low back pain and existence of anomalies in LS spine (transitional vertebra- TV and/or Spina bifida occulta SBO) also have the degeneration of the intervertebral disc (DD) L4-L5 and/or L5-S1. This prospective study included 69 patients from 8 to 16 years of age (X 12.81) of whom 40 were male (57.97%), and 29 female (42.03%). They all were examinated in University of Zagreb, "Sestre milosrdnice" University Hospital Center, Zagreb Children's Hospital, Department of Orthopaedic, Zagreb, Croatia. The reason of their visit was non specific low back pain. Pain was measured by visual analog scale (VAS) and mean score was three, duration of pain was between two and four weeks. Also, pain was sporadic, during daytime and not connected with level of physical activity. They all have undergone an algorithm of radiological examinations. Standard AP and LL radiographs (RTG) were made, as well as magnetic resonance (MR) of LS spine and sacrum in sagittal and transversal plane in T1 and T2 weighted sequence. The anomalies of L5 and S1 were found in 65 patients: transitional vertebra classified according to Castellvi et al. and SBO. In MRI in T2 weighted sequence DD was found in 61 patients which was classified modified from Pearce. Data analysis and comparison showed that 56patients with TV and/or SBO have changes on vertebral dynamic segment L5-S1 (VDS) and that means DD. In 13 patients only DD or spinal anomaly (TV and/or SBO) were found. Correlation between anomalies and DD in those patients was established by McNemar analysis and has shown significant difference (p=0.581) in favour of the patients with anomaly and DD. This has established that all of 56 patients with spinal anomaly could have DD as known cause of LBP.


Subject(s)
Intervertebral Disc Degeneration/complications , Low Back Pain/etiology , Lumbar Vertebrae/pathology , Sacrum/pathology , Spina Bifida Occulta/complications , Adolescent , Child , Female , Humans , Intervertebral Disc Degeneration/pathology , Low Back Pain/pathology , Magnetic Resonance Imaging , Male , Prospective Studies , Spina Bifida Occulta/pathology
7.
Thromb Res ; 129(5): 652-9, 2012 May.
Article in English | MEDLINE | ID: mdl-21840572

ABSTRACT

Recently, in rat abdominal aorta terminoterminal-anastomosis the stable gastric pentadecapeptide BPC 157 prevents obstructive thrombus formation and rapidly destroys already formed obstructive thrombus. Also, BPC 157 wound healing may signify the clot as conductive matrix or "scaffold" to speed up wound healing process, and decrease bleeding. Here, in rats, BPC 157 (10 µg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0 g/kg i.p. once), and amputation associated with those agents application. BPC 157 counteracting regimens (i.v., i.p., i.g. (immediately after any challenge)) correspondingly follow the route of bleeding-agents application. All heparin-, warfarin-, and aspirin-rats and normal-rats that received BPC 157 exhibited lesser fall in platelets count. BPC 157 attenuated over-increased APTT-, TT-values in 10mg/kg heparin-rats, but did not influence heparin activity (anti-Xa test). Indicatively, unless counteracted in BPC 157 rats, excessive bleeding-acute thrombocytopenia (<20% of initial values in heparin-rats) approaches substantial fall in platelets count known in type II HIT. Also, BPC 157 markedly prolongs the survival time (heparin-rats, 25mg/kg, right foot amputation).


Subject(s)
Anti-Ulcer Agents/pharmacology , Aspirin/pharmacology , Heparin/pharmacology , Peptide Fragments/pharmacology , Proteins/pharmacology , Thrombocytopenia/blood , Thrombocytopenia/drug therapy , Warfarin/pharmacology , Animals , Bleeding Time , Male , Rats , Rats, Wistar , Wound Healing/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...